Noonan syndrome (NS) is a multisystem disorder caused by mutations that affect the RAS–MAPK pathway, and it is associated with an increased propensity for proliferative disorders. This retrospective cross-sectional study examined patients with NS followed between January 2000 and January 2025. The investigators reviewed clinical, anthropometric, laboratory, and cranial MRI data obtained at diagnosis and during follow-up. Statistical analyses were performed using SPSS version 29.0. Ethical approval was granted by the Ankara University Faculty of Medicine Human Research Ethics Committee.
Cranial abnormalities were identified in 54.1% of the patients included in this series. The reported abnormalities constituted a broad spectrum, ranging from structural cranial anomalies to clinically significant intracranial neoplastic lesions. The authors emphasize that the distribution of findings included both non-neoplastic structural changes and tumors affecting the central nervous system, but the abstract does not provide a detailed breakdown of lesion types or absolute numbers by category.
A key observation in the cohort was that some intracranial lesions were asymptomatic at the time of imaging. Because clinically significant lesions may present without symptoms, reliance on clinical assessment alone could fail to identify relevant intracranial pathology. The presence of asymptomatic but potentially clinically important lesions underpins the authors’ position that neuroimaging can provide diagnostic information not evident from history and examination alone.
The study reports that during follow-up, no newly detected pathologies or malignancies emerged among patients receiving recombinant growth hormone therapy. Based on these observations, the authors interpret the absence of incident malignancy during follow-up as supportive evidence for the safety of growth hormone treatment in this population. The abstract does not specify durations of follow-up, numbers of treated patients, or tumor surveillance intervals; those details were not reported in the abstract.
Given the high frequency of cranial abnormalities and the occurrence of asymptomatic lesions, the authors recommend consideration of cranial MRI at the time of diagnosis in patients with Noonan syndrome. They particularly highlight the relevance of baseline neuroimaging when planning initiation of growth hormone therapy, to identify intracranial lesions that could influence clinical management. The recommendation arises from the finding that cranial MRI can detect structural and neoplastic abnormalities that clinical evaluation may miss.
This work used a retrospective review of patients with NS spanning a 25-year window (January 2000 to January 2025). Clinical, anthropometric, laboratory, and cranial MRI data were included when available. Statistical analysis was performed using SPSS version 29.0. Ethical approval and consent processes were addressed: the study was approved by the Ankara University Faculty of Medicine Human Research Ethics Committee, and informed consent for publication of images was obtained where applicable. The authors declare no competing interests.
Limitations apparent from the abstract include lack of granular detail on sample size, the exact prevalence of specific lesion types, imaging protocols, duration and completeness of follow-up, and the numbers of patients treated with growth hormone. The abstract does not provide these itemized data points; thus, readers should consult the full article for comprehensive methodological and numerical details.
Recognize that patients with Noonan syndrome may harbor a variety of cranial abnormalities detectable on MRI; more than half in this series had such findings.
Understand that some clinically significant intracranial lesions can be asymptomatic; baseline neuroimaging can reveal pathology not evident on examination.
Consider ordering cranial MRI at diagnosis, especially when a patient with NS is being evaluated for growth hormone therapy, to document baseline intracranial status prior to treatment decisions.
Note that, in this cohort, no new malignancies were reported during follow-up among patients receiving growth hormone, which the authors interpret as supportive of therapy safety; however, the abstract does not detail follow-up duration or treated cohort size.
Clinicians and centers managing patients with Noonan syndrome should weigh these findings alongside existing guidelines and institutional practices, and review the complete study for detailed data to inform policy on baseline neuroimaging and surveillance.